Form 4: Guardant Health CEO's Stock Vesting & Tax Withholding

Guardant Health Co-CEO AmirAli Talasaz reported the vesting of restricted stock units and subsequent tax-related share dispositions.

Summary

• AmirAli Talasaz, Co-Chief Executive Officer and Director of Guardant Health, Inc. (GH), reported transactions involving common stock and restricted stock units (RSUs).
• On September 30, 2025, 4,814 shares of common stock were acquired due to the vesting of RSUs, increasing direct beneficial ownership to 1,988,479 shares.
• Concurrently on September 30, 2025, 2,440 shares were disposed of at a price of $62.48 per share to cover tax withholding obligations related to the RSU vesting, resulting in a beneficial ownership of 1,986,039 shares.
• On October 1, 2025, an additional 23,997 shares of common stock were acquired from RSU vesting, bringing direct beneficial ownership to 2,010,036 shares.
• Also on October 1, 2025, 12,162 shares were disposed of at a price of $62.65 per share for tax withholding purposes, adjusting beneficial ownership to 1,997,874 shares.
• The 4,814 RSUs vested on September 30, 2025, were part of an award granted on March 12, 2025, vesting in four equal quarterly installments.
• The 23,997 RSUs vested on October 1, 2025, were part of an award granted on March 18, 2024, with 33% vesting on January 1, 2025, and the remainder vesting quarterly over two years.

Sentiment

Score: 5

Explanation: The filing reports routine, pre-scheduled insider transactions related to executive compensation and tax obligations. It does not contain information that would significantly alter the perception of the company's financial health, operational performance, or strategic direction, thus warranting a neutral sentiment.

Positives

• The vesting of restricted stock units indicates the continued equity compensation and retention of a key executive, aligning management's interests with shareholders.

Negatives

• The disposition of shares for tax withholding purposes, while standard, results in a reduction of the executive's direct share ownership.

Risks

• No specific risks beyond general market risks affecting the value of Guardant Health's common stock are mentioned in this routine insider transaction report.

Future Outlook

This Form 4 filing reports past insider transactions and does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing represents a routine insider transaction related to executive compensation, which is a standard practice across publicly traded companies in all industries. It does not provide specific insights into broader industry trends or competitive positioning.

Comparison to Industry Standards

• The vesting of restricted stock units and subsequent disposition of shares for tax withholding are standard components of executive compensation packages across the industry.
• The specific amounts and vesting schedules are determined by Guardant Health's compensation committee and are consistent with typical equity incentive plans designed to align executive interests with long-term shareholder value.

Related Party Transactions

• The reported transactions are related to the compensation of AmirAli Talasaz, a Co-Chief Executive Officer and Director of Guardant Health, Inc., which is a standard related-party transaction in the context of executive compensation.

Stakeholder Impact

• Shareholders: The transactions represent a routine aspect of executive compensation, with a minor, pre-scheduled dilution effect from RSU vesting and a corresponding reduction in direct insider ownership due to tax-related sales. This is generally expected and does not typically have a significant impact on shareholder value.
• Employees: No direct impact on employees beyond the executive involved.

Next Steps

• Remaining quarterly vesting installments for the restricted stock unit award granted on March 12, 2025, with the final installment on December 31, 2025.
• Remaining quarterly vesting installments for the restricted stock unit award granted on March 18, 2024, over the next two years.

Key Dates

Recommendation

This Form 4 reports routine vesting of restricted stock units and subsequent share dispositions for tax obligations by a Co-CEO. Such transactions are standard components of executive compensation and do not typically indicate a change in the company's fundamental outlook or warrant a shift in investment recommendation based solely on this filing. Investors should consider broader company performance and market conditions.

Keywords

Guardant Health, GH, AmirAli Talasaz, Form 4, SEC filing, insider transaction, stock vesting, restricted stock units, RSU, tax withholding, beneficial ownership, executive compensation